Robert A. Bradway

Chairman and Chief Executive Officer, Amgen

Appears in 1 story

Born: 1963

Education: Amherst College, Harvard University, Harvard Business School

Last updated Nov 2, 2026

Stories

Tarlatamab rewrites treatment for small-cell lung cancer as approvals spread worldwide

New Capabilities

As of May 2026: Leading Amgen's oncology expansion strategy

For decades, patients with extensive-stage small-cell lung cancer who relapsed after chemotherapy had almost nowhere to turn — five-year survival rates sat around 3%. Now a drug that bridges the patient's immune cells to their tumor has won approval in both the United States and China.

Updated May 31